(ABBV) stock has risen 22.8% over the past year, after a modest 0.6% gain in the last week and a 7.7% pullback over the past month. Wall Street’s analysts are moderately bullish, forecasting a move from the last close of $207.94 to an average 12‑month target of $254.06.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
This implies meaningful upside for investors willing to ride out short‑term volatility in AbbVie’s share price. The ModerateBuy consensus suggests that, while not a screaming bargain, the stock is still viewed favorably by the analyst community.
One of the key voices backing AbbVie is Vamil Divan of Guggenheim Securities, who reiterated a Buy rating on the stock on April 10, 2026, and lifted his price target to $249. That target points to solid upside from current levels and aligns closely with the broader Street forecast.
Divan expects AbbVie’s first‑quarter 2026 results, due April 29, to be broadly in line with company guidance, projecting revenue of $14.65 billion and earnings of $2.57 per share. He notes that the gap with consensus EPS likely stems from some analysts not fully incorporating a $0.41 dilution from a one‑time IPR&D charge, which pulled official EPS guidance down to $2.56–$2.60.
According to TipRanks, this 5‑star analyst ranks 690 out of 12,068, with a success rate of about 56.3% and an average return of 9.8% per rating, adding weight to his bullish stance on AbbVie. Never miss a stock rating. Find all the latest ratings on TipRanks’ Top Wall Street Analysts page.